Targeting the gene in Friedreich ataxia

被引:13
|
作者
Hebert, Michael D. [1 ]
机构
[1] Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA
关键词
triplet repeat; neurodegenerative; HDAC inhibitors; DNA binding; frataxin;
D O I
10.1016/j.biochi.2007.12.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pathological expansions of GAA repeats in the first intron of the frataxin gene cause most cases of Friedreich ataxia, a progressively debilitating neurodegenerative disease. The disease is inherited in an autosomal recessive manner and the GAA repeats are suspected to form unusual non B-DNA conformations that decrease transcription and subsequently reduce levels of the encoded protein, frataxin. Recent work has shown that GAA repeats induce heterochromatin formation and silencing of the frataxin gene locus. Frataxin plays a crucial role in iron metabolism and detoxification and interacts with electron transport chain proteins. Clinical trials are currently underway to examine the efficacy of antioxidants in the treatment of Friedreich ataxia, but therapeutics designed to increase frataxin message levels are still in the developmental stages. This review will focus on the progress of potential treatment strategies for Friedreich ataxia that target the GAA expanded gene and seek to increase the level of frataxin message and protein. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:1131 / 1139
页数:9
相关论文
共 50 条
  • [41] Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia
    Pandolfo, Massimo
    Reetz, Kathrin
    Darling, Alejandra
    de Rivera, Francisco Javier Rodriguez
    Henry, Pierre-Gilles
    Joers, James
    Lenglet, Christophe
    Adanyeguh, Isaac
    Deelchand, Dinesh
    Mochel, Fanny
    Pousset, Francoise
    Pascual, Silvia
    Van den Eede, Delphine
    Martin-Ugarte, Itziar
    Vila-Brau, Anna
    Mantilla, Adriana
    Pascual, Maria
    Martinell, Marc
    Meya, Uwe
    Durr, Alexandra
    NEUROLOGY-GENETICS, 2022, 8 (06)
  • [42] The role of oxidative stress in Friedreich's ataxia
    Lupoli, Federica
    Vannocci, Tommaso
    Longo, Giovanni
    Niccolai, Neri
    Pastore, Annalisa
    FEBS LETTERS, 2018, 592 (05) : 718 - 727
  • [43] Role of Uric Acid in Friedreich Ataxia neurodegeneration
    Trinchillo, A.
    De Rosa, A.
    Sacca, F.
    MOVEMENT DISORDERS, 2021, 36 : S18 - S20
  • [44] An Overview of the Ferroptosis Hallmarks in Friedreich's Ataxia
    Turchi, Riccardo
    Faraonio, Raffaella
    Lettieri-Barbato, Daniele
    Aquilano, Katia
    BIOMOLECULES, 2020, 10 (11) : 1 - 15
  • [45] Friedreich's ataxia: Past, present and future
    Marmolino, Daniele
    BRAIN RESEARCH REVIEWS, 2011, 67 (1-2) : 311 - 330
  • [46] Clinical Experience With Deferiprone Treatment for Friedreich Ataxia
    Elincx-Benizri, Sandra
    Glik, Amir
    Merkel, Drorit
    Arad, Michael
    Freimark, Dov
    Kozlova, Evgenia
    Cabantchik, Ioav
    Hassin-Baer, Sharon
    JOURNAL OF CHILD NEUROLOGY, 2016, 31 (08) : 1036 - 1040
  • [47] Mitochondrial dysfunction in neurons in Friedreich's ataxia
    Stepanova, Anna
    Magrane, Jordi
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2020, 102
  • [48] Small molecules affecting transcription in Friedreich ataxia
    Gottesfeld, Joel M.
    PHARMACOLOGY & THERAPEUTICS, 2007, 116 (02) : 236 - 248
  • [49] Friedreich's ataxia: Clinical aspects and pathogenesis
    Pandolfo, M
    SEMINARS IN NEUROLOGY, 1999, 19 (03) : 311 - 321
  • [50] A Review of Friedreich Ataxia Clinical Trial Results
    Perlman, Susan L.
    JOURNAL OF CHILD NEUROLOGY, 2012, 27 (09) : 1217 - 1222